drugset / Trial / NCT04624178
A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
Phase 2
Active not recruiting
20 enrolled
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb · collabClovis Oncology, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out whether combining the study drugs rucaparib and nivolumab may be an effective treatment for advanced and/or metastatic LMS, and whether the study treatment works as well as the standard chemotherapy for this type of cancer.
Timeline
- Start
- 2020-11-05
- Primary completion
- 2025-11-17
- Completion
- 2026-11-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |
| Subject | Rucaparib | Small molecule | 600 mg | Oral |